Roof Eidam & Maycock ADV maintained its position in shares of Pfizer, Inc. (NYSE:PFE) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 24,300 shares of the biopharmaceutical company’s stock at the end of the second quarter. Roof Eidam & Maycock ADV’s holdings in Pfizer were worth $816,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of PFE. Boston Partners increased its stake in Pfizer by 7.3% in the 1st quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock worth $830,071,000 after buying an additional 1,649,801 shares during the period. Bank of Nova Scotia increased its stake in Pfizer by 325.9% in the 1st quarter. Bank of Nova Scotia now owns 1,934,514 shares of the biopharmaceutical company’s stock worth $66,180,000 after buying an additional 1,480,258 shares during the period. Fisher Asset Management LLC increased its stake in Pfizer by 3.9% in the 2nd quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock worth $1,143,248,000 after buying an additional 1,275,832 shares during the period. State of Tennessee Treasury Department increased its stake in Pfizer by 22.7% in the 1st quarter. State of Tennessee Treasury Department now owns 4,891,784 shares of the biopharmaceutical company’s stock worth $167,348,000 after buying an additional 904,413 shares during the period. Finally, Mn Services Vermogensbeheer B.V. increased its stake in Pfizer by 499.4% in the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 972,122 shares of the biopharmaceutical company’s stock worth $32,654,000 after buying an additional 809,933 shares during the period. 69.09% of the stock is currently owned by institutional investors.
WARNING: “Pfizer, Inc. (PFE) Stake Held by Roof Eidam & Maycock ADV” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2017/09/15/pfizer-inc-pfe-stake-held-by-roof-eidam-maycock-adv.html.
Several research analysts recently commented on the stock. Berenberg Bank reaffirmed a “hold” rating and issued a $36.00 price target (down previously from $39.00) on shares of Pfizer in a research note on Tuesday, August 15th. BMO Capital Markets reaffirmed a “buy” rating and issued a $37.00 price target on shares of Pfizer in a research note on Thursday. BidaskClub raised shares of Pfizer from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price target on the stock. in a research note on Wednesday. Finally, Cowen and Company set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $37.72.
In related news, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the sale, the insider now directly owns 145,649 shares in the company, valued at $5,097,715. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ian C. Read sold 197,168 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the sale, the chief executive officer now owns 580,318 shares in the company, valued at $19,730,812. The disclosure for this sale can be found here. Insiders have sold 464,521 shares of company stock worth $15,813,961 over the last 90 days. Insiders own 0.06% of the company’s stock.
Shares of Pfizer, Inc. (NYSE PFE) traded down 0.95% on Friday, hitting $35.39. 13,047,079 shares of the stock were exchanged. The stock has a market cap of $210.48 billion, a PE ratio of 25.89 and a beta of 1.00. The company’s 50 day moving average is $33.58 and its 200-day moving average is $33.52. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.84.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same period in the prior year, the firm earned $0.64 earnings per share. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. Analysts predict that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, September 1st. Investors of record on Friday, August 4th were paid a dividend of $0.32 per share. The ex-dividend date of this dividend was Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.58%. Pfizer’s payout ratio is 94.12%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.